OTCMKTS:BAYRY Bayer Aktiengesellschaft (BAYRY) Stock Price, News & Analysis $5.74 +0.15 (+2.68%) As of 02/20/2025 03:59 PM Eastern Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartDividendEarningsFinancialsHeadlinesInsider TradesSEC FilingsShort Interest About Bayer Aktiengesellschaft Stock (OTCMKTS:BAYRY) 30 days 90 days 365 days Advanced Chart View Price History Chart DataSkip Price History Chart Get BAYRY alerts:Sign Up Key Stats Today's Range$5.68▼$5.7750-Day Range$4.85▼$5.7452-Week Range$4.79▼$8.58Volume324,343 shsAverage Volume887,985 shsMarket Capitalization$22.56 billionP/E RatioN/ADividend Yield0.35%Price TargetN/AConsensus RatingHold Company OverviewBayer Aktiengesellschaft, together its subsidiaries, operates as a life science company worldwide. It operates through Pharmaceuticals, Consumer Health, and Crop Science segments. The Pharmaceuticals segment offers prescription products primarily for cardiology and women's health care; specialty therapeutics in the areas of oncology, hematology, and ophthalmology; and diagnostic imaging equipment and digital solutions, and contrast agents, as well as cell and gene therapy. The Consumer Health segment markets nonprescription over-the-counter medicines for self-medication and self-care; and solutions for nutritional supplements, allergy, cough and cold, dermatology, pain and cardiovascular risk prevention, and digestive health. This segment also provides breeding, propagation, and production/processing of seeds, including seed dressing. The company has a collaboration with Acuitas Therapeutics, Inc. to strengthen gene editing programs; Peking University in the area of basic pharmaceutical research; the Swiss Tropical and Public Health Institute in the development of the compound emodepside for the treatment of infection with soil-transmitted helminths; bit.bio Ltd. for the discovery and manufacture of regulatory T cells for use in creating therapeutics; Hologic, Inc. in the field of contrastenhanced-mammography solutions to improve diagnostic imaging for the detection of breast cancer; and Twist Bioscience Corporation centering around the research and development of antibody-based pharmaceuticals, as well as with CrossBay Medical Inc. It distributes its products through wholesalers, pharmacies and pharmacy chains, supermarkets, online and other retailers, and hospitals, as well as directly to farmers. The company has collaboration with Thermo Fisher Scientific. Bayer Aktiengesellschaft was founded in 1863 and is based in Leverkusen, Germany.Read More… Receive BAYRY Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Bayer Aktiengesellschaft and its competitors with MarketBeat's FREE daily newsletter. Email Address BAYRY Stock News HeadlinesTranscript: Vincent Kompany's Press Conference Ahead Of Bayern Munich vs Bayer Leverkusen In The BundesligaFebruary 14, 2025 | msn.comPredicted XIs | Bayer Leverkusen vs Bayern MunichFebruary 14, 2025 | sports.yahoo.comTop Picks for Trump’s Pro-Crypto America10,000% Crypto Opportunities in 2025 27 of the brightest minds in crypto share exclusive intel… February 21, 2025 | Crypto 101 Media (Ad)Bayer price target lowered to EUR 26 from EUR 30 at Morgan StanleyFebruary 12, 2025 | markets.businessinsider.comBayer backs broadened effort to shield Roundup from claims it failed to warn of cancerFebruary 11, 2025 | msn.comMiddle East & Africa Pharmaceuticals Market Report 2025: Presents Country-Level Growth Trends and Shares to 2030 - Julphar (Gulf Pharmaceutical), Bayer Middle East, Niner Pharmaceuticals Lead the CompetitionFebruary 6, 2025 | globenewswire.comBerenberg Bank Reaffirms Their Hold Rating on Bayer (0P6S)January 29, 2025 | markets.businessinsider.comJ.P. Morgan Sticks to Their Hold Rating for Bayer (0P6S)January 21, 2025 | markets.businessinsider.comSee More Headlines BAYRY Stock Analysis - Frequently Asked Questions How have BAYRY shares performed this year? Bayer Aktiengesellschaft's stock was trading at $4.88 on January 1st, 2025. Since then, BAYRY stock has increased by 17.6% and is now trading at $5.74. View the best growth stocks for 2025 here. How were Bayer Aktiengesellschaft's earnings last quarter? Bayer Aktiengesellschaft (OTCMKTS:BAYRY) issued its quarterly earnings results on Tuesday, November, 12th. The company reported $0.07 EPS for the quarter, missing analysts' consensus estimates of $0.17 by $0.10. The business earned $10.96 billion during the quarter. Bayer Aktiengesellschaft had a negative net margin of 2.02% and a positive trailing twelve-month return on equity of 16.90%. Does Bayer Aktiengesellschaft have any subsidiaries? Bayer Aktiengesellschaft subsidiaries include Asklepios BioPharmaceutical, Care/of, KaNDy Therapeutics, BlueRock Therapeutics, Monsanto Company, Zoner.ag, Dihon Pharmaceutical, and more. How do I buy shares of Bayer Aktiengesellschaft? Shares of BAYRY stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Company Calendar Last Earnings11/12/2024Today2/20/2025Next Earnings (Estimated)3/04/2025Fiscal Year End12/31/2025Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeOTCMKTS SectorMedical Industry Pharmaceutical preparations Sub-IndustryN/A Current SymbolOTCMKTS:BAYRY CUSIPN/A CIK1144145 Webwww.bayer.com Phone49214301Fax49-21-4306-6328Employees99,723Year Founded1863Profitability EPS (Most Recent Fiscal Year)($0.26) Trailing P/E RatioN/A Forward P/E Ratio4.38 P/E GrowthN/ANet Income$-3,183,040,000.00 Net Margins-2.02% Pretax Margin-3.59% Return on Equity16.90% Return on Assets4.94% Debt Debt-to-Equity Ratio1.19 Current Ratio1.32 Quick Ratio0.81 Sales & Book Value Annual Sales$51.55 billion Price / Sales0.44 Cash Flow$4.52 per share Price / Cash Flow1.27 Book Value$9.11 per share Price / Book0.63Miscellaneous Outstanding Shares3,929,700,000Free FloatN/AMarket Cap$22.56 billion OptionableNot Optionable Beta1.04 Social Links Metaverse Stocks And Why You Can't Ignore ThemThinking about investing in Meta, Roblox, or Unity? Enter your email to learn what streetwise investors need to know about the metaverse and public markets before making an investment.Get This Free Report This page (OTCMKTS:BAYRY) was last updated on 2/21/2025 by MarketBeat.com Staff From Our PartnersCollect $7k per month from Tesla’s SECRET dividendTesla doesn't pay a traditional dividend.... But I just discovered a secret backdoor to collect a secret 69...Investors Alley | SponsoredElon “obliterates” Bill Gates?All 10 of the world's biggest money managers follow my work, and the Pentagon, the FBI and Harvard professors ...Altimetry | SponsoredNVDA Crash UpdateAn overseas AI rival sent shockwaves through the U.S. tech market last week... Leaving millions of investor...Chaikin Analytics | Sponsored$2 Trillion Disappears Because of Fed's Secretive New Move$2 trillion has disappeared from the US government's books. The reason why is a new, secretive move being c...Stansberry Research | SponsoredHas Trump finally met his match?Dylan Jovine predicted the 2008 crash over a year before it happened. Folks who listened to him had the chance...Behind the Markets | Sponsored My 2025 AI BlueprintI first recommended Bitcoin at $300 in 2013 … before it went up 33,645%. Now, I am revealing my 2025 AI Blu...Weiss Ratings | Sponsored Is Starlink Set For The Largest IPO In History?He turned PayPal from a tiny, off-the-radar startup… to a massive $64 billion giant. Then, he did it again ...Paradigm Press | SponsoredBetter than Bitcoin – and potentially more profitableThe world is obsessed with Bitcoin again... And for a good reason: It just soared beyond $100,000. Bitcoin ...Brownstone Research | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Bayer Aktiengesellschaft Please log in to your account or sign up in order to add this asset to your watchlist. Share Bayer Aktiengesellschaft With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.